This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?
by Zacks Equity Research
CI benefits from improved premiums resulting from an extensive customer base. Buyouts and adequate operating cash flows are other tailwinds.
Select Medical Agrees to Acquire Valir Rehabilitation Hospital
by Zacks Equity Research
SEM enters a definitive agreement to acquire Valir Rehabilitation Hospital and expand its inpatient rehabilitation footprint in Oklahoma City.
Ensign Adds 8 Facilities in Kansas & Colorado to Expand Footprint
by Zacks Equity Research
The acquisition deals increase ENSG's portfolio to encompass 323 healthcare operations spanning 14 states.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
Centene Stock Rises 29% in a Year: Evaluating the Road Ahead
by Zacks Equity Research
CNC gains from improved premiums and service revenues, acquisitions and adequate operating cash flows.
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
by Zacks Equity Research
HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.
Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Ensign Group, Inc. (ENSG) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Acadia Healthcare Expands Behavioral Health Services in Iowa
by Zacks Equity Research
ACHC breaks ground on a new behavioral health hospital in Council Bluffs, addressing regional care shortages through a joint venture with Methodist Health System.
Ensign Group (ENSG) Up 50% in Past Year: More Growth on the Horizon?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of improved skilled services revenues, higher rental revenues and adequate operating cash flows.
Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.
Here's Why Investors Should Hold Acadia (ACHC) Stock for Now
by Zacks Equity Research
Acadia Healthcare (ACHC) remains well-poised for growth on the back of the solid demand for behavioral healthcare services, continuous pursuit of expansion initiatives and a notable financial position.
Should Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OMFS
Why Ensign Group (ENSG) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Acadia Healthcare (ACHC) Shares Up 12% on Q2 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results reflect higher revenue per patient day and increased patient days. It currently estimates 2024 adjusted EPS within $3.45-$3.65 compared with the earlier view of $3.40-$3.70.
Here's Why Ensign Group (ENSG) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
by Zacks Equity Research
Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.
Ensign Group (ENSG) Q2 Earnings Beat on Occupancy, Stock Up 7.2%
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancy and skilled services revenue. Higher expenses partially offset the results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Ensign Group (ENSG) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 2.33% and 1.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Here's Why You Should Retain Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of solid segmental contributions, an expanding healthcare portfolio and sound cash reserves.